Trade SABS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
SAB Biotherapeutics, Inc. (SABS) is trading at US$3.08, down 0.96% today as of Nov 12, 16:00 EST. The company has a market capitalisation of US$284.35M. Over the past 52 weeks, SABS has traded between US$2.44 and US$5.15. On Syfe you can trade SABS with $0 commission and add it to your watchlist.
| Previous close | US$3.11 |
|---|---|
| Market cap | US$284.35M |
| 52-week range | US$2.44 – US$5.15 |
| Volume | 2.11M |
| Exchange | US |
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
Year: 2021
SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes
Oct 13, 1:17 PM · MT Newswires
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target
Jun 24, 11:37 AM · MT Newswires
Chardan Adjusts Price Target on SAB Biotherapeutics to $16 From $14, Maintains Buy Rating
Jun 17, 10:51 AM · MT Newswires
SAB Biotherapeutics, Inc. (SABS) stock is trading at US$3.08, -0.96% from the previous close of US$3.11.
The market cap for SAB Biotherapeutics, Inc. (SABS) stock is approximately US$284.35M.
The 52-week high for SAB Biotherapeutics, Inc. (SABS) stock is US$5.15.
The 52-week low for SAB Biotherapeutics, Inc. (SABS) stock is US$2.44.
SAB Biotherapeutics, Inc. (SABS) does not currently pay a dividend.
Stay on top of SABS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
